Larimar Therapeutics Inc (NASDAQ: LRMR) kicked off on Tuesday, up 3.68% from the previous trading day, before settling in for the closing price of $3.26. Over the past 52 weeks, LRMR has traded in a range of $1.61-$9.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 50.78% over the past five years. While this was happening, its average annual earnings per share was recorded -45.50%. With a float of $36.46 million, this company’s outstanding shares have now reached $64.03 million.
Let’s look at the performance matrix of the company that is accounted for 65 employees. In terms of profitability, gross margin is 33.2%, operating margin of -43711.2%, and the pretax margin is -39514.94%.
Larimar Therapeutics Inc (LRMR) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Larimar Therapeutics Inc is 43.06%, while institutional ownership is 62.24%.
Larimar Therapeutics Inc (LRMR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.49 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -45.50% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.80% during the next five years compared to 50.78% growth over the previous five years of trading.
Larimar Therapeutics Inc (NASDAQ: LRMR) Trading Performance Indicators
Take a look at Larimar Therapeutics Inc’s (LRMR) current performance indicators. Last quarter, stock had a quick ratio of 7.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.49, a number that is poised to hit -0.48 in the next quarter and is forecasted to reach -1.92 in one year’s time.
Technical Analysis of Larimar Therapeutics Inc (LRMR)
Larimar Therapeutics Inc (NASDAQ: LRMR) saw its 5-day average volume 0.73 million, a negative change from its year-to-date volume of 0.97 million. As of the previous 9 days, the stock’s Stochastic %D was 31.02%.
During the past 100 days, Larimar Therapeutics Inc’s (LRMR) raw stochastic average was set at 85.51%, which indicates a significant increase from 65.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.25 in the past 14 days, which was higher than the 0.24 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.68, while its 200-day Moving Average is $3.99. Nevertheless, the first resistance level for the watch stands at $3.52 in the near term. At $3.67, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.80. If the price goes on to break the first support level at $3.24, it is likely to go to the next support level at $3.11. Assuming the price breaks the second support level, the third support level stands at $2.96.
Larimar Therapeutics Inc (NASDAQ: LRMR) Key Stats
The company with the Market Capitalisation of 216.41 million has total of 64,028K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -80,600 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -29,280 K.
